Advertisement

Topics

Search Results for "Benzodiazepine Multiple Sclerosis"

16:32 EDT 27th April 2017 | BioPortfolio

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Amyotrophic lateral sclerosis ALS

Diffuse mesangial sclerosis

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

[Series] Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the unde...

Positive multiple sclerosis clinical trial suggests 'unprecedented' effects in relapsing form of the disease

In findings that show the effectiveness of a new strategy for treating multiple sclerosis (MS), researchers are reporting positive results from three large, international, multicenter Phase III clinic...

Resetting the Immune System to Stop Multiple Sclerosis

A clinical trial led by Imperial College London has revealed the potential of a risky new therapy to stop the progression of multiple sclerosis. Worldwide, there are 2.3 million people with multiple s...

[Articles] Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study

More frequent use of health care in patients with multiple sclerosis than in controls in the 5 years before a first demyelinating event, according to health administrative data, suggests the existence...

A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa

Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed promising results for the treatment of multipl...

Ocrelizumab for Multiple Sclerosis

A Phase III trial of ocrelizumab in primary-progressive multiple sclerosis and two Phase III trials of ocrelizumab in relapsing-remitting multiple sclerosis have demonstrated efficacy with treatment.

Helius Medical Technologies Announces Publication of Multiple Sclerosis Pilot Study Results in Multiple Sclerosis Journal: Experimental, Translational and Clinical

Thursday, February 9th 2017 at 5:00pm UTC NEWTOWN, Pa.–(BUSINESS WIRE)– Helius Medical Technologies, Inc. (TSX: HSM, HSM.S, OTCQB: HSDT) (« Helius ») is pleased to anno...

Multiple Sclerosis Current and Future Players Prices from USD $2995

Multiple Sclerosis Current and Future PlayersSummaryGlobalData has released its pharma report, Multiple Sclerosis Current and Future Players. The report is a vital source of uptodate information wit...

Matching PubMed Articles

Corrigendum.

Corrigendum to Ragheb, S et al. (2011). Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid Multiple Sclerosis Journal 17(07) 819-829. [DOI: 10.1177/1352458511398887].

Temperature dependence of multiple sclerosis mortality rates in the United States.

It is well known that multiple sclerosis (MS) patients are very sensitive to heat events. However, how MS patients respond to the significant temperature difference between the high- and low-latitude ...

Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.

Previous studies have suggested a relationship between neuroanatomical and neurofunctional hippocampal alterations and episodic memory impairments in multiple sclerosis (MS) patients.

Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers.

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.

Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable measure of diffuse tissue damage.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement